CYP19A1 and erythema multiforme: To date, selective progesterone receptor modulators (SPRMs) (Song et al., 2018), oral contraceptives (Grandi et al., 2019), mifepristone (RU486) (Song et al., 2018), Levonorgestrel system (LNGN-ius) (Song et al., 2018), and aromatase inhibitors (Suardika and Pemayun, 2018) have been employed in treating EM.